{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:46:11Z","timestamp":1790232371435,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Ann Plast Surg"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hyperpigmentation is a skin disorder characterized by a localized darkening of the skin due to increased melanin production. When patients fail first line topical treatments, secondary treatments such as chemical peels and lasers are offered. However, these interventions are not devoid of risks and are associated with postinflammatory hyperpigmentation. In the quest for novel therapeutic potentials, this study aims to investigate computational methods in the identification of new targeted therapies in the treatment of hyperpigmentation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used a comprehensive approach, which integrated text mining, interpreting gene lists through enrichment analysis and integration of diverse biological information (GeneCodis), protein-protein association networks and functional enrichment analyses (STRING), and plug-in network centrality parameters (Cytoscape) to pinpoint genes closely associated with hyperpigmentation. Subsequently, analysis of drug-gene interactions to identify potential drugs (Cortellis) was utilized to select drugs targeting these identified genes. Lastly, we used Deep Learning Based Drug Repurposing Toolkit (DeepPurpose) to conduct drug-target interaction predictions to ultimately identify candidate drugs with the most promising binding affinities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Thirty-four hyperpigmentation-related genes were identified by text mining. Eight key genes were highlighted by utilizing GeneCodis, STRING, Cytoscape, gene enrichment, and protein-protein interaction analysis. Thirty-five drugs targeting hyperpigmentation-associated genes were identified by Cortellis, and 29 drugs, including 16 M2PK1 inhibitors, 11 KRAS inhibitors, and 2 BRAF inhibitors were recommended by DeepPurpose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The study highlights the promise of advanced computational methodology for identifying potential treatments for hyperpigmentation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/sap.0000000000004007","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T22:00:27Z","timestamp":1718834427000},"page":"S30-S42","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Precision Drug Repurposing"],"prefix":"10.1097","volume":"93","author":[{"given":"Shuwei","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Saad","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Lineaweaver","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Big Data and Artificial Intelligence Center, Zhongshan Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"bib1-20250327","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/pcmr.12986","article-title":"Management of hyperpigmentation: current treatments and emerging therapies","volume":"34","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"bib2-20250327","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1590\/abd1806-4841.20142353","article-title":"Acquired hyperpigmentations","volume":"89","year":"2014","journal-title":"An Bras Dermatol"},{"key":"bib3-20250327","first-page":"401","article-title":"Hyperpigmentation: an overview of the common afflictions","volume":"16","year":"2004","journal-title":"Dermatol Nurs"},{"key":"bib4-20250327","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2017.05.009","article-title":"The impact of skin hyperpigmentation and hyperchromia on quality of life: a cross-sectional study","volume":"77","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"bib5-20250327","first-page":"46","article-title":"Willingness-to-pay and time trade-off: the burden of disease in patients with benign hyperpigmentation","volume":"12","year":"2019","journal-title":"J Clin Aesthet Dermatol"},{"key":"bib6-20250327","first-page":"1994","article-title":"Loss of melanogenic properties in tyrosinases induced by glucosylation inhibitors within malignant melanoma cells","volume":"42","year":"1982","journal-title":"Cancer Res"},{"key":"bib7-20250327","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/1523-1747.ep12542192","article-title":"Selective aberration and pigment loss in melanosomes of malignant melanoma cells in vitro by glycosylation inhibitors: premelanosomes as glycoprotein","volume":"81","year":"1983","journal-title":"J Invest Dermatol"},{"key":"bib8-20250327","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/1523-1747.ep12664554","article-title":"Transfer mechanism of melanosomes in epidermal cell culture","volume":"67","year":"1976","journal-title":"J Invest Dermatol"},{"key":"bib9-20250327","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/1523-1747.ep12258559","article-title":"Mitotic activity of epidermal melanocytes in UV-irradiated mouse skin","volume":"70","year":"1978","journal-title":"J Invest Dermatol"},{"key":"bib10-20250327","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/2221081a0","article-title":"Racial differences in the fate of melanosomes in human epidermis","volume":"222","year":"1969","journal-title":"Nature"},{"key":"bib11-20250327","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.3390\/ijms10062440","article-title":"An updated review of tyrosinase inhibitors","volume":"10","year":"2009","journal-title":"Int J Mol Sci"},{"key":"bib12-20250327","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2017.01.036","article-title":"Postinflammatory hyperpigmentation: a comprehensive overview: treatment options and prevention","volume":"77","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"bib14-20250327","first-page":"S33","article-title":"Post-inflammatory hyperpigmentation occuring after cosmetic procedures [in French]","volume":"143","year":"2016","journal-title":"Ann Dermatol Venereol"},{"key":"bib15-20250327","doi-asserted-by":"crossref","first-page":"e24716","DOI":"10.1371\/journal.pone.0024716","article-title":"pubmed2ensembl: a resource for mining the biological literature on genes","volume":"6","year":"2011","journal-title":"PLoS One"},{"issue":"Web Server issue","key":"bib16-20250327","first-page":"W317","article-title":"GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information","volume":"37","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"bib17-20250327","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"bib18-20250327","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1093\/bioinformatics\/btp517","article-title":"Analyzing biological network parameters with CentiScaPe","volume":"25","year":"2009","journal-title":"Bioinformatics"},{"issue":"suppl 4suppl(4)","key":"bib19-20250327","first-page":"S11","article-title":"cytoHubba: identifying hub objects and sub-networks from complex interactome","volume":"8","year":"2014","journal-title":"BMC Syst Biol"},{"key":"bib20-20250327","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"22\u201323","key":"bib21-20250327","first-page":"5545","article-title":"DeepPurpose: a deep learning library for drug-target interaction prediction","volume":"36","year":"2021","journal-title":"Bioinformatics"},{"key":"bib22-20250327","first-page":"229","article-title":"Selumetinib: a selective MEK1 inhibitor for solid tumor treatment","volume":"23","year":"2023","journal-title":"Clin Exp Med"},{"key":"bib23-20250327","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2174\/138161213804547187","article-title":"Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway","volume":"19","year":"2013","journal-title":"Curr Pharm Des"},{"key":"bib24-20250327","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1468-2494.2010.00616.x","article-title":"The melanogenesis and mechanisms of skin-lightening agents\u2013existing and new approaches","volume":"33","year":"2011","journal-title":"Int J Cosmet Sci"},{"key":"bib25-20250327","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"bib26-20250327","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","year":"2002","journal-title":"Nature"},{"key":"bib27-20250327","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.semdp.2015.02.010","article-title":"BRAF V600E mutation-specific antibody: a review","volume":"32","year":"2015","journal-title":"Semin Diagn Pathol"},{"key":"bib28-20250327","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-14-0776","article-title":"FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation","volume":"20","year":"2014","journal-title":"Clin Cancer Res"},{"key":"bib29-20250327","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"bib30-20250327","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"bib31-20250327","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib32-20250327","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"bib33-20250327","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","year":"2015","journal-title":"Mol Cancer Res"},{"key":"bib34-20250327","first-page":"178","article-title":"Many faces of Ras activation","volume":"1786","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"bib35-20250327","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/genes12050662","article-title":"The role of wild-type RAS in oncogenic RAS transformation","volume":"12","year":"2021","journal-title":"Genes (Basel)"},{"key":"bib36-20250327","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1474-4422(07)70075-3","article-title":"Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective","volume":"6","year":"2007","journal-title":"Lancet Neurol"},{"key":"bib37-20250327","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00381-020-04731-2","article-title":"Current status of MEK inhibitors in the treatment of plexiform neurofibromas","volume":"36","year":"2020","journal-title":"Childs Nerv Syst"},{"key":"bib38-20250327","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-09-4254","article-title":"A mouse model of melanoma driven by oncogenic KRAS","volume":"70","year":"2010","journal-title":"Cancer Res"},{"key":"bib39-20250327","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/humu.22514","article-title":"TP53 mutants in the tower of babel of cancer progression","volume":"35","year":"2014","journal-title":"Hum Mutat"},{"key":"bib40-20250327","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.cell.2006.12.045","article-title":"Central role of p53 in the suntan response and pathologic hyperpigmentation","volume":"128","year":"2007","journal-title":"Cell"},{"key":"bib41-20250327","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1074\/jbc.M805570200","article-title":"The essential role of p53 in hyperpigmentation of the skin via regulation of paracrine melanogenic cytokine receptor signaling","volume":"284","year":"2009","journal-title":"J Biol Chem"},{"key":"bib42-20250327","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/sj.onc.1206451","article-title":"PTEN signaling pathways in melanoma","volume":"22","year":"2003","journal-title":"Oncogene"},{"key":"bib43-20250327","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1073\/pnas.95.16.9418","article-title":"In vitro loss of heterozygosity targets the PTEN\/MMAC1 gene in melanoma","volume":"95","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib44-20250327","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0962-8924(99)01519-6","article-title":"PTEN: a tumour suppressor that functions as a phospholipid phosphatase","volume":"9","year":"1999","journal-title":"Trends Cell Biol"},{"key":"bib45-20250327","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81663-3","article-title":"Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association","volume":"99","year":"1999","journal-title":"Cell"},{"key":"bib46-20250327","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1086\/340026","article-title":"Protean PTEN: form and function","volume":"70","year":"2002","journal-title":"Am J Hum Genet"},{"key":"bib47-20250327","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-4608(00)00353-8","article-title":"PTEN\/MMAC1 in malignant melanoma and its importance for tumor progression","volume":"125","year":"2001","journal-title":"Cancer Genet Cytogenet"},{"key":"bib48-20250327","first-page":"2881","article-title":"Loss of PTEN promotes tumor development in malignant melanoma","volume":"63","year":"2003","journal-title":"Cancer Res"},{"key":"bib49-20250327","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/MOP.0000000000000923","article-title":"PIK3CA vascular overgrowth syndromes: an update","volume":"32","year":"2020","journal-title":"Curr Opin Pediatr"},{"key":"bib50-20250327","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"bib51-20250327","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","year":"2012","journal-title":"Cell"},{"key":"bib52-20250327","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/jid.2013.511","article-title":"A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms","volume":"134","year":"2014","journal-title":"J Invest Dermatol"},{"key":"bib53-20250327","doi-asserted-by":"crossref","first-page":"e43369","DOI":"10.1371\/journal.pone.0043369","article-title":"Novel somatic mutations to PI3K pathway genes in metastatic melanoma","volume":"7","year":"2012","journal-title":"PloS One"},{"key":"bib54-20250327","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"bib55-20250327","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-019-1230-z","article-title":"Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models","volume":"38","year":"2019","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Annals of Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SAP.0000000000004007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T08:12:01Z","timestamp":1743322321000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SAP.0000000000004007"}},"subtitle":["A Deep Learning Toolkit for Identifying 34 Hyperpigmentation-Associated Genes and Optimizing Treatment Selection"],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":54,"journal-issue":{"issue":"2S","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/sap.0000000000004007","relation":{},"ISSN":["1536-3708","0148-7043"],"issn-type":[{"value":"1536-3708","type":"electronic"},{"value":"0148-7043","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,18]]}}}